Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Frontline NALIRIFOX Regimen Improves OS in Metastatic Pancreatic Ductal Adenocarcinoma

November 9th 2022

The NALIRIFOX regimen significantly improved overall survival over nab-paclitaxel plus gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma, meeting the primary end point of the phase 3 NAPOLI 3 trial.

Advanced Biliary Tract Cancers: Novel Biomarker Strategies

November 9th 2022

Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.

Novel Agents Being Explored in Advanced Biliary Tract Cancers

November 9th 2022

Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.

Second-line HR070803 Plus 5-FU/Leucovorin Improves OS in Gemcitabine-Refractory Pancreatic Cancer

November 7th 2022

The liposome formulation of irinotecan, HR070803, in combination with 5-fluororacil and leucovorin provided a statistically significant overall survival benefit to patients with gemcitabine-refractory locally advanced or metastatic pancreatic cancer.

Dr. Maron on the Role of PD-1 Inhibition in Esophagogastric Cancer

November 4th 2022

Steven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.

Treatment Options for Advanced HCC in the Second-Line and Beyond

November 4th 2022

Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.

Novel First-Line Immunotherapy Approaches in Advanced HCC

November 4th 2022

Panelists close out their discussion on first-line treatment options for advanced HCC with a review of single-agent and combination immunotherapy approaches.

FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma

November 3rd 2022

Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.

FDA Grants Orphan Drug Designation to OTX-2002 for Hepatocellular Carcinoma

November 2nd 2022

The FDA has granted an orphan drug designation to OTX-2002 for the treatment of patients with hepatocellular carcinoma.

Sequencing Therapy in Patients With Advanced Biliary Tract Cancers

November 2nd 2022

In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.

Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse Events

November 2nd 2022

Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.

FOLFIRINOX Provides Prolonged PFS Benefit Over Gemcitabine in Locally Advanced Pancreatic Carcinoma

November 1st 2022

Treatment with FOLFIRINOX resulted in a significantly longer progression-free survival than that achieved with gemcitabine in patients with locally advanced pancreatic carcinoma, meeting the primary end point of the phase 3 NEOPAN trial.

Future Directions: Optimizing Care Through Combinations

November 1st 2022

Tanios S. Bekaii-Saab, MD, describes the future direct of clinical research into immune check point inhibitors for solid tumors, which he believes will be to explore additional combinations with targeted therapies.

Novel Investigational Combination Strategies

November 1st 2022

Tanios S. Bekaii-Saab, MD, provides insight into ongoing research exploring novel combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors across solid tumors.

FDA Grants Fast Track Designation to ITM-11 for Gastroenteropancreatic Neuroendocrine Tumors

October 28th 2022

The FDA has granted a fast track designation to 177Lu-edotreotide for use as a potential therapeutic option in patients with gastroenteropancreatic neuroendocrine tumors.

Real-World Use of Durvalumab + Tremelimumab in Advanced HCC

October 28th 2022

In the context of clinical data from the HIMALAYA and STRIDE trials, expert oncologists review real-world use of tremelimumab + durvalumab in advanced HCC.

Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab

October 28th 2022

Focusing on a second patient profile of advanced hepatocellular carcinoma, panelists consider the role of first-line tremelimumab + durvalumab.

Antidrug Antibodies Against Atezolizumab Associated With Poor Outcomes in HCC

October 27th 2022

Highly elevated levels of antidrug antibodies against atezolizumab were associated with poorer clinical outcomes for patients who received atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations

October 26th 2022

Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.

TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers

October 26th 2022

Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.